Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Teijin Pharma","sponsor":"TransThera Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$1,250.0 million","upfrontCash":"Undisclosed","newsHeadline":"Takeda Completes Sale of Four Diabetes Products in Japan to Teijin Pharma Limited","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teijin Receives Additional Approval in Japan for Botulinum Toxin Type A Xeomin \u00ae From Merz","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$230.0 million","upfrontCash":"$30.0 million","newsHeadline":"Teijin Pharma Grants Global Exclusive License for Investigational Small Molecule Candidate in Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Nephrology","graph2":"Preclinical"},{"orgOrder":0,"company":"Teijin Pharma","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","amount":"$245.0 million","upfrontCash":"$70.0 million","newsHeadline":"Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"November 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Teijin Pharma

    Menu

    Teijin Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Teijin Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan

              Details:

              Under the agreement, Teijin will receive exclusive license to further develop and commercialize TransCon hGH (lonapegsomatropin-tcgd), TransCon PTH, and TransCon CNP for endocrinology rare disease, in Japan.

              Lead Product(s): Lonapegsomatropin

              Therapeutic Area: Endocrinology Product Name: TransCon hGH

              Highest Development Status: Phase III Product Type: Large molecule

              Recipient: Ascendis Pharma

              Deal Size: $245.0 million Upfront Cash: $70.0 million

              Deal Type: Licensing Agreement November 29, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Teijin Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Teijin Pharma Grants Global Exclusive License for Investigational Small Molecule Candidate in Kidney Disease

              Details:

              Teijin will grant Novartis exclusive worldwide rights to research, develop, manufacture and commercialize an investigational small molecule candidate for proteinuric kidney diseases. The candidate is believed to impact the pathogenesis of multiple kidney diseases.

              Lead Product(s): Undisclosed

              Therapeutic Area: Nephrology Product Name: Undislcosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

              Deal Size: $230.0 million Upfront Cash: $30.0 million

              Deal Type: Licensing Agreement March 06, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Teijin Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Teijin Receives Additional Approval in Japan for Botulinum Toxin Type A Xeomin ® From Merz

              Details:

              Xeomin ® is effective in the treatment of peripheral cholinergic nerve endings by decreasing the contraction of voluntary muscles, and relieves muscle tone by inhibiting the release of a neurotransmitter, acetylcholine.

              Lead Product(s): IncobotulinumtoxinA

              Therapeutic Area: Neurology Product Name: Xeomin

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Merz Pharma

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 23, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Teijin Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Takeda Completes Sale of Four Diabetes Products in Japan to Teijin Pharma Limited

              Details:

              The portfolio divested to Teijin Pharma was comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.

              Lead Product(s): Alogliptin Benzoate,Pioglitazone

              Therapeutic Area: Endocrinology Product Name: Liovel

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Takeda Pharmaceutical

              Deal Size: $1,250.0 million Upfront Cash: Undisclosed

              Deal Type: Divestment April 01, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Teijin Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited

              Details:

              The portfolio to be divested to Teijin Pharma is comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.

              Lead Product(s): Alogliptin Benzoate

              Therapeutic Area: Endocrinology Product Name: Nesina

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Takeda Pharmaceutical

              Deal Size: $1,250.0 million Upfront Cash: Undisclosed

              Deal Type: Divestment February 26, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Teijin Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Japan
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration

              Details:

              Teijin Pharma and TransThera will establish a joint drug discovery collaboration of multiple drug targets with the immediate goal of acquiring compounds as candidates for new drug development based on the targets and compounds found by Teijin Pharma.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: TransThera Biosciences

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration December 18, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY